Description
A large retrospective cohort study across multiple databases evaluated the cardiovascular safety of commonly used NSAIDs in over 48,000 patients with recent serious coronary heart disease.
Naproxen showed the lowest risk of serious coronary and cardiovascular events. Short-term use of ibuprofen, diclofenac, celecoxib, and rofecoxib was linked to higher cardiovascular risk. High doses of rofecoxib (>25 mg) and celecoxib (>200 mg) significantly increased coronary risk.
Among patients with coronary heart disease, naproxen demonstrated a more favorable cardiovascular safety profile compared to diclofenac, ibuprofen, and high-dose COX-2 inhibitors.